Dr. Reddy's Is BofA's Top Pick In Indian Pharma On Earnings Visibility
BofA has chosen Dr. Reddy's Laboratories Ltd. as its top pick in the Indian pharma space, as its sees earnings visibility in the near term. Two years of outperformance-boosted valuation and gross margin tailwinds point to positive earnings momentum, BoFA said.
The brokerage has a 'buy' rating on Dr. Reddy's Laboratories Ltd. It has raised the target price to Rs 1,620 apiece, implying a 24% upside.
The pharma firm's outperformance for the past two consecutive years has taken the valuation to 17–27% premium to long-term average of the sector. This reflected the relative earnings in the near-term, compared to downside risks in other sectors. The US generic medicine pricing environment, and pipeline support in the first half of calendar year 2025 will add to the growth momentum.
However, there's limited visibility of the US generic medicine business beyond the first half of 2025, particularly with generic Revlimid. Dr. Reddy's generic Revlimid's contribution to earnings has been offset by lower revenue concentration, compared to peers in the base business.
Revlimid is an anti-cancer drug. It is taken orally to treat blood cancers such as multiple myeloma.
In the near term, less competition in generic medicine launches and contribution from new drivers will likely support growth. Dr. Reddy's Laboratories' effort to create a global over-the-counter platform should help alleviate concerns on earnings dependence on the US generic medicine business.
In the second half, Dr. Reddy's Laboratories will focus on research and development monetisation and new growth drivers to support premium valuations, BofA said in its note.
Overall, BofA remains cautious on Indian pharma stocks as margin expansion in a competitive, but slowing volume growth market could be tough. The risks include regulatory action in domestic pharma and potential policies impacting the US generic medicine business dynamics.
Dr. Reddy's Laboratories Share Price Today
Dr. Reddy's Laboratories Ltd.'s share price fell 1.13% to Rs 1,288 apiece. It erased all losses to trade 0.13% higher at Rs 1,304.45 apiece as of 1:06 p.m., as compared to a 0.39% decline in the NSE Nifty 50.
The stock rose 15.44% in 12 months. The relative strength index was at 43.75.
Out of 40 analysts tracking the company, 15 maintain a 'buy' rating, 12 recommend a 'hold' and 13 suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 6.0%.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
